Objective:To report an acute myeloid leukemia(AML)with insertion translocations of ins(21;8)(q22.1;q22q24),and to investigate its clincal and laborator characteristics.Methods:Bone marrow cells were cultured by 24 hours,following which chromosomes were harvested and analyzed by R-banding karyotype.Reverse transcription polymerase chain reaction(RT-PCR)was used to screen for 53 leukemia-realted fusion genes.The illumina high-throughput sequence was employed to detect AML-related gene mutations.Fianlly,the patient's clinical manifestations,laboratory findings,and treatment response were comprehensively analyzed.Results:The karyotype of this patient was 46,XX,ins(21;8)(q22.1;q22q24)[20].RT-PCR detected the presence of the RUNX1/RUNX1T1(AML1/ETO)fusion gene.The AML-associated gene mutation screening identified Class Ⅰ mutation in CALR,Class Ⅱ mutations in EZH2,ASXL2,and RAD21,and Class Ⅲ mutation in CREBBP.Conclusion:The ins(21;8)(q22.1;q22q24)is a rare insertion variant translocation of t(8;21)(q22;q22),requires expanded case studies to clarify its clinical features and prognostic implications in AML patients with this mutation.

Objective:To report an acute myeloid leukemia(AML)with insertion translocations of ins(21;8)(q22.1;q22q24),and to investigate its clincal and laborator characteristics.Methods:Bone marrow cells were cultured by 24 hours,following which chromosomes were harvested and analyzed by R-banding karyotype.Reverse transcription polymerase chain reaction(RT-PCR)was used to screen for 53 leukemia-realted fusion genes.The illumina high-throughput sequence was employed to detect AML-related gene mutations.Fianlly,the patient's clinical manifestations,laboratory findings,and treatment response were comprehensively analyzed.Results:The karyotype of this patient was 46,XX,ins(21;8)(q22.1;q22q24)[20].RT-PCR detected the presence of the RUNX1/RUNX1T1(AML1/ETO)fusion gene.The AML-associated gene mutation screening identified Class Ⅰ mutation in CALR,Class Ⅱ mutations in EZH2,ASXL2,and RAD21,and Class Ⅲ mutation in CREBBP.Conclusion:The ins(21;8)(q22.1;q22q24)is a rare insertion variant translocation of t(8;21)(q22;q22),requires expanded case studies to clarify its clinical features and prognostic implications in AML patients with this mutation.

This study is to investigate the effects of paeoniflorin on cerebral blood flow and the balance of PGI2/TXA2 of rats with focal cerebral ischemia-reperfusion injury. A total of 72 SD rats (3) were randomly divided into 6 groups: sham operation group, cerebral ischemia-reperfusion model group (I/R gourp), low (10 mg.kg-1), middle (20 mg.kg-1) and high (40 mg.kg-1) doses of paeoniflorin groups and nimrnodipine group. Focal cerebral ischemia in rats was made by inserting a monofilament suture into internal carotid artery for 90 min and then reperfused for 24 h. The effects of paeoniflorin on neurological deficit scores and the infarction volume of brain were detected. Relative regional cerebral blood flow (rCBF) was continuously monitored over ischemic hemispheres by laser-Doppler flowmetry (LDF). The expression of COX-2 in hippocampal CAl region was estimated by immunohistochemistry and the contents of prostacyclin I2 (PGI2), thromboxane A2 (TXA2), and ratio of PGIJ2/TXA2 in serum were measured by ELISA kits. Paeoniflorin significantly ameliorated neurological scores, reduced the infarction volume, and increased regional cerebral blood flow relative to the I/R group. In addition, paeoniflorin could inhibit COX-2 expression and the release of TXA2 and prevent the downregulation of PGI2 induced by I/R injury. The neuroprotective effects of paeoniflorin against focal cerebral ischemia-reperfusion rats might be attributed to improve the supply of injured hemisphere blood flow and adjust the balance between PGI2/TXA2.